Bo Jiang1, Yumei Chen2, Guoen Yao3, Cunshan Yao4, Hongmei Zhao5, Xiangdong Jia6, Yunyan Zhang7, Junling Ge8, Enchao Qiu9, Chengyun Ding10. 1. Department of Neuromedical Center, The First Hospital Affiliated to the Chinese PLA General Hospital, 51 Fucheng Avenue, Beijing, 100048, Haidian District, China. bojicn@yeah.net. 2. Department of Neuromedical Center, The First Hospital Affiliated to the Chinese PLA General Hospital, 51 Fucheng Avenue, Beijing, 100048, Haidian District, China. zhaohuiang@163.com. 3. Department of Neuromedical Center, The First Hospital Affiliated to the Chinese PLA General Hospital, 51 Fucheng Avenue, Beijing, 100048, Haidian District, China. linauu@126.com. 4. Department of Neuromedical Center, The First Hospital Affiliated to the Chinese PLA General Hospital, 51 Fucheng Avenue, Beijing, 100048, Haidian District, China. liiauang@126.com. 5. Department of Neuromedical Center, The First Hospital Affiliated to the Chinese PLA General Hospital, 51 Fucheng Avenue, Beijing, 100048, Haidian District, China. uihang@126.com. 6. Department of Neuromedical Center, The First Hospital Affiliated to the Chinese PLA General Hospital, 51 Fucheng Avenue, Beijing, 100048, Haidian District, China. eiinghou@163.com. 7. Department of Neuromedical Center, The First Hospital Affiliated to the Chinese PLA General Hospital, 51 Fucheng Avenue, Beijing, 100048, Haidian District, China. xiangu@yeah.net. 8. Department of Neuromedical Center, The First Hospital Affiliated to the Chinese PLA General Hospital, 51 Fucheng Avenue, Beijing, 100048, Haidian District, China. wijawang@163.com. 9. Department of Neuromedical Center, The First Hospital Affiliated to the Chinese PLA General Hospital, 51 Fucheng Avenue, Beijing, 100048, Haidian District, China. zhumeiwang@yeah.net. 10. Department of Neuromedical Center, The First Hospital Affiliated to the Chinese PLA General Hospital, 51 Fucheng Avenue, Beijing, 100048, Haidian District, China. chengyundingcn@163.com.
Abstract
BACKGROUND: Vascular cognitive impairment-no dementia (VCIND) refers to the early or mild cognitive impairment induced by cerebral vascular injury. Research shows that serum total homocysteine (tHcy) level is an independent risk factor for cerebral vascular disease and may be closely related to cognitive function.Current studies on the tHcy level in VCIND patients are limited, and the relationship of tHcy with cognitive function remains unclear. This study aims to investigate the tHcy levels in patients with VCIND and to determine their correlation with cognitive function, as well as to provide useful clues for preventing and treating VCIND. METHODS: The tHcy, folate, and vitamin B12 levels in 82 patients with VCIND were reviewed retrospectively and compared with those of 80 stroke patients without cognitive impairment and 69 healthy controls by using the Montreal Cognitive Assessment (MoCA) scale and the event-related potential P300 to evaluate cognitive function. RESULTS: The tHcy levels in the VCIND group were higher than those in the other two groups, whereas the folate and Vitamin B12 levels in the VCIND group were lower than those of the other two groups. The tHcy levels in the stroke group were higher than those in the control group, and the folate and vitamin B12 levels in the stroke group were lower than those in the control group. The patients in the VCIND group with high tHcy exhibited lower MoCA scores and prolonged P300 latency than those in with normal tHcy. Correlation analysis showed that tHcy level is positively correlated with P300 latency period and negatively correlated with MoCA score. CONCLUSION: The tHcy levels were significantly higher and the vitamin B12 and folate levels were significantly lower in the patients with VCIND than those in the other groups. The high tHcy levels in the VCIND patients may be correlated with impaired cognitive function.
BACKGROUND:Vascular cognitive impairment-no dementia (VCIND) refers to the early or mild cognitive impairment induced by cerebral vascular injury. Research shows that serum total homocysteine (tHcy) level is an independent risk factor for cerebral vascular disease and may be closely related to cognitive function.Current studies on the tHcy level in VCINDpatients are limited, and the relationship of tHcy with cognitive function remains unclear. This study aims to investigate the tHcy levels in patients with VCIND and to determine their correlation with cognitive function, as well as to provide useful clues for preventing and treating VCIND. METHODS: The tHcy, folate, and vitamin B12 levels in 82 patients with VCIND were reviewed retrospectively and compared with those of 80 strokepatients without cognitive impairment and 69 healthy controls by using the Montreal Cognitive Assessment (MoCA) scale and the event-related potential P300 to evaluate cognitive function. RESULTS: The tHcy levels in the VCIND group were higher than those in the other two groups, whereas the folate and Vitamin B12 levels in the VCIND group were lower than those of the other two groups. The tHcy levels in the stroke group were higher than those in the control group, and the folate and vitamin B12 levels in the stroke group were lower than those in the control group. The patients in the VCIND group with high tHcy exhibited lower MoCA scores and prolonged P300 latency than those in with normal tHcy. Correlation analysis showed that tHcy level is positively correlated with P300 latency period and negatively correlated with MoCA score. CONCLUSION: The tHcy levels were significantly higher and the vitamin B12 and folate levels were significantly lower in the patients with VCIND than those in the other groups. The high tHcy levels in the VCINDpatients may be correlated with impaired cognitive function.
Vascular cognitive impairment-no dementia (VCIND) refers to the early or mild cognitive impairment induced by cerebral vascular injury. The illness is relatively hidden, and the degree of cognitive impairment has not yet reached the diagnostic standard for dementia [1]. VCIND has an incidence of 39.5% within 1 year after a stroke [2]. Early diagnosis and intervention improve the prognosis of VCINDpatients, which would otherwise progress into dementia [3]. Considering its reversibility, VCIND has become a hot research topic. Research shows that serum total homocysteine (tHcy) level is an independent risk factor for cerebral vascular disease [4] and may be closely related to cognitive function [5]. Current studies on the tHcy level in VCINDpatients are limited, and the relationship of tHcy with cognitive function remains unclear. This study aims to investigate the tHcy levels in patients with VCIND and to determine their correlation with cognitive function, as well as to provide useful clues for preventing and treating VCIND.
Participants and methods
Participants
From January 2008 to January 2013, 367 new strokepatients were screened from the Department of Internal Medicine of the First Affiliated Hospital of PLA General Hospital. All the strokepatients performed the cognitive function detection on the post-onset seventh day, first month, and third month. The patient would be enrolled in the study when the VCIND inclusion criteria were met. The detection of related indicators such as folate, vitamin B12, tHcy, and P300 were completed within 48 h of enrollment. Among 97 patients that met the VCIND inclusion criteria, 5 refused to join the experiment, and 10 were not enrolled because they had severe internal diseases or took medication that would affect tHcy. Finally, 82 VCINDpatients were recruited. Currently, there are no unified diagnostic criteria of VCIND, and different studies might use different diagnostic criteria [3,6]. In our study, VCIND was diagnosed according to the Rockwood criteria [7] as follows: existing cerebrovascular disease; evidence of cognitive impairment under neuropsychological assessment; the cognitive impairment occurred within 3 months after stroke; causal relationship between cerebrovascular disease and cognitive impairment, excluding other diseases; Hanchinski ischemia index ≥7; does not conform to the diagnostic criteria for dementia revised by the United States of America Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). The exclusion criteria were as follows: 1) Alzheimer’s patients; 2) other cognitive disorders, mental illness, or hemiplegic aphasia and other diseases that might influence their Montreal score and P300 determination; 3) taking medications that affect tHcy levels within the past 1 month (such as contraceptives, anti-epileptic drugs, dopamine drugs, and folate and/or vitamin B12); 4) the presence of diseases that affect central nervous system function, such as thyroid disease, severe anemia, vitamin B12 and folate deficiency, and severe malnutrition, as well as serious liver, kidney, and other organic diseases.A total of 80 outpatient and hospitalized strokepatients were enrolled in the study. Stroke was diagnosed in accordance with the diagnostic criteria [8], revised by the 2003 European Stroke Promotion Association, and was confirmed by MRI scanning and scale detection, as well as via clinical and cognitive function detection without cognitive impairment.The control group consisted of 69 healthy controls who were also in the First Affiliated Hospital of PLA General Hospital. The cranial MRI showed no obvious lesion, and the clinical and cognitive function determination did not found obvious impairment. This study was conducted in accordance with the declaration of Helsinki, and was conducted with approval from the Ethics Committee of the First Hospital Affiliated to the Chinese PLA General Hospital. Written informed consent was obtained from all participants.
Methods
tHcy, folate, and vitamin B12 detection
Fasting venous blood samples (2–3 mL), which were centrifuged to obtain serum after 30 min, were drawn from each subject. The tHcy concentration was determined via enzymatic conversion on a Hitachi 7180 automatic biochemical analyzer (Tokyo, Japan) using a kit provided by Beijing Nine Strong Biological Technology Co. Ltd. (Beijing, China). The tHcy levels ranged from 5 to 14 μmol/L. Hyperhomocysteinemia (Hhcy) was defined as a level >14 μmol/L. Vitamin B12 and folate levels were determined from 3 to 4 mL of venous blood using an Access automated chemiluminescent microparticle immunoassay system and the related kit (BECKMAN Company USA).
Cognitive function tests
Cognitive function was evaluated using the Montreal Cognitive Assessment scale (MoCA) [9]. The MoCA includes eight cognitive domains and eleven checking contents, including visuospatial ability, naming, memory, attention and calculation, language fluency, abstract thinking, delayed memory, and directional force. The highest possible score is 30 points. Participants who had less than 12 years of schooling were given an additional point in their final score. Higher scores indicate better cognitive function. The impairment assessment criterion was a MoCA <26.
P300 potential measurement
All of the patients underwent a P300 determination within 48 h by using the British Oxford multimedia EMG/EP system. In a quiet, shielded room, the participants were instructed to lie in a supine position, stay awake, and concentrate. In accordance with International EEG 10–20 system, recording electrodes were placed in the central line. The reference electrode was placed on the right lobe, with frontal grounding. The inter electrode impedance was <5 KΩ, and the analysis time was 600 ms. Using Tone Pip stimuli, the probability of the non-target stimuli (1000 Hz) was set to 80% with a magnitude of 80 dB with gradations. The target stimulus (4000 Hz) was set to 20% probability with a magnitude of 90 dB and was interspersed randomly with the non-target stimuli. The participants were instructed to respond to the target stimulus by knobbing the key. The instrument automatically recorded the reaction time. The test was repeated twice, and the mean score was used in the data analysis.
Statistical analysis
Data were analyzed using SPSS16.0 software. The recorded data are expressed as mean ± SD and were compared using an analysis of variance and a t-test. Nonparametric Mann–Whitney U tests were performed on the level of the variable. Count data are expressed as percentages and compared using a χ2 test. Correlation analysis was performed via Pearson correlation analysis. Differences with P <0.05 were considered significant.
Results
Characteristics of the participants
Among the 82 VCINDpatients, 73 were inpatients and 9 were outpatients, 49 were male and 33 were female, and were 41–78 years old, with a mean age of 64 ± 3.14 years. The educational background of the patients varied, with 14 cases reaching university, 57 cases reaching high school, and 11 cases reaching junior high school. The National Institutes of Health Stroke Scale (NIHSS) score was 5.17 ± 1.45, including 35 diabetic, 41 hypertensive, and 29 hyperlipidemic patients.Of the 80 strokepatients, 51 were male and 29 were female, with ages ranging from 37 to 77 years and a mean age of 62 ± 2.79 years. The educational status of the patients varied as follows: 13 received a university education, 53 reached high school, and 14 reached junior high school. Their NIHSS score was 4.77 ± 1.79, including those of 31 diabetic, 37 hypertensive, and 27 hyperlipidemic patients.The control group consisted of 42 males and 27 females and included 11 diabetic, 16 hypertensive, and 15 hyperlipidemicpatients. Their ages ranged from 41 to 72 years, with a mean age of 61 ± 1.89 years. Their educational backgrounds were as follows: 17 received a university education, 45 reached high school, and 7 reached junior high school.
Comparison of general states
The three groups did not differ significantly differ in terms of age (based on the ANOVA, P >0.05), gender, culture level, and the proportion of patients (based on the χ2, P >0.05). The VCIND group did not differ from the stroke group in terms of NIHSS (Mann–Whitney U test, P >0.05). The VCIND group did not differ significantly from the stroke group in terms of the incidence of diabetes, hypertension, and hyperlipidemia (χ2, P >0.05).
Cognitive function
The VCIND group had significantly lower MoCA scores (22.81 ± 1.67) than did the other two groups (P <0.01). The stroke group (27.77 ± 1.03) did not differ significantly from the control group (28.23 ± 0.91) in terms of the total MoCA score (P >0.05).
tHcy, folate, and vitamin B12
The tHcy level in the VCIND group was higher than that of the other two groups. The folate and the vitamin B12 levels in the VCIND group were lower than those in the other two groups. The tHcy level in the stroke group was higher than that in the control group, and the folate and vitamin B12 levels were lower than those in the control group (Table 1).
Table 1
Comparison of serum tHcy (μmol/L), folate (ng/ml), Vitamin B
12
(pg/ml) level between the three groups
Group
Cases (n)
tHcy
Folate
Vitmin B12
VCIND
82
22.14 ± 6.92a
8.01 ± 3.13a
280.85 ± 96.72b
Stroke
80
16.36 ± 7.17d
12.61 ± 3.56c
367.53 ± 127.30c
Control
69
11.86 ± 4.47
16.42 ± 4.91
495.18 ± 102.79
F
13.36
22.81
20.14
P
<0.001
<0.001
<0.001
Note: Compared with the other two groups: a
P < 0.01, b
P < 0.05; compared with the control group, c
P < 0.01, d
P < 0.05.
Comparison of serum tHcy (μmol/L), folate (ng/ml), Vitamin B
12
(pg/ml) level between the three groupsNote: Compared with the other two groups: a
P < 0.01, b
P < 0.05; compared with the control group, c
P < 0.01, d
P < 0.05.
Determination of P300
The prolongation of the P300 latency period in the VCIND group was significantly longer than that in the stroke and control groups (P <0.01). The prolongation in the P300 latency period in the stroke group did not differ significantly from that in the control group (P >0.05). The three groups did not differ significantly in terms of P300 amplitude (P >0.05), which is shown in Table 2.
Table 2
Comparison of the central midline P300 latency period(MS) and amplitude (μV) between the three groups
Group
Cases (n)
P300 latency
P300 amplitude
VCIND
82
396.68 ± 76.67a
3.86 ± 0.87
Stroke
80
307.20 ± 50.45
3.80 ± 0.78
Control
69
306.13 ± 70.33
3.83 ± 0.69
F
12.04
0.028
P
0.028
0.973
Note: Compared with the other group, a
P < 0.01.
Comparison of the central midline P300 latency period(MS) and amplitude (μV) between the three groupsNote: Compared with the other group, a
P < 0.01.
Comparison of MoCA and P300 in the VCIND group
In the VCIND group, 45 patients exhibited Hhcy. The patients with Hhcy had lower MoCA scores and prolongation in the P300 latency period than the patients with normal tHcy, but the P300 amplitude did not differ significantly between the groups (Table 3).
Table 3
Comparison of MoCA, P300 between the Hhcy (tHcy > 14 μmol/L) group and normal tHcy group in VCIND group
Groups
Cases (n)
MoCA
P300 latency
P300 amplitude
Normal tHcy
37
23.71 ± 0.91a
371.67 ± 31.79a
3.88 ± 0.60
Hhcy
45
21.53 ± 1.36
429.07 ± 41.87
3.73 ± 0.78
t
5.041
4.229
0.561
P
<0.001
<0.001
>0.05
Note: a
P < 0.01.
Comparison of MoCA, P300 between the Hhcy (tHcy > 14 μmol/L) group and normal tHcy group in VCIND groupNote: a
P < 0.01.
Correlation between the tHcy, folate, vitamin B12, P300 latency period, and MoCA in the VCIND group
The tHcy levels in the VCIND group patients were correlated with their P300 latency periods and MoCA scores. The tHcy levels were negatively correlated with MoCA score (r = −0.468, P = 0.038) and were positively correlated with the P300 latency period (r = 0.740, P = 0.014). The folate level was positively correlated with MoCA score (r = 0.509, P = 0.022), and the vitamin B12 level was positively correlated with MoCA score (r = 0.588, P = 0.006).
Discussion
tHcy is a thiol-containing amino acid generated from methionine through in vivo metabolism [10]. Many studies have shown that high tHcy levels are related to cognitive function damage [11-13]. The influence of tHcy on the cognitive functions of VCINDpatients has important clinical significance.The tHcy levels in the VCIND and stroke groups were higher than in the normal group. This finding suggests that tHcy levels are correlated with the pathogenesis of stroke and is consistent with the current research results. Specifically, tHcy is an independent risk factor for cerebral vascular disease [14,15]. The tHcy levels in the VCIND group were higher than those in the stroke group, which suggests that cognitive function may be correlated with tHcy levels.Previous studies on the relationship between tHcy and cognitive function differ in their findings [16-18]. Different ethnic groups have different apolipoprotein E (ApoE) genes, which may be associated with cognitive function [19]. Currently, it is considered that the cognitive impairment caused by tHcy occurs through direct and indirect paths; the direct path involves increasing glutamate excitotoxicity, thereby reducing neuronal DNA repair capacity and accelerating the formation of oxidative stress and A β and damage on hippocampal neurons, which leads to cognitive impairment. The indirect path involves vascular endothelial cell dysfunction and lipid metabolic disorder, leading to cerebral vascular disease to cause impairment of cognitive function [20-22]. A certain randomized, double-blind clinical trial showed that reduced tHcy could not necessarily improve cognitive functions [23,24] and, thus, suggested that the current mechanism of the damages of cognitive functions caused by tHcy was not entirely clear.The patients in the VCIND group exhibited higher tHcy levels than those in the other two groups. Within the VCIND group, the MoCA score of the patients with high tHcy was lower than those with normal tHcy. Furthermore, correlation analysis shows that tHcy level is negatively correlated with MoCA, which suggests that tHcy levels may be closely associated with impaired cognitive function.The P300 event-related potential is an objective electrophysiologic examination that reflects brain cognition function [25,26]. Related research has shown that patients with mild cognitive impairment exhibit changes in P300 [27]. The P300 latency period reflects the evaluation time of stimuli in cognitive activities, which is an index for information processing speed [28], reflecting to a certain degree the perception, attention, memory, information coding, and cognitive integration speed brain function state [29]. The results of this study show that the P300 latency period in the VCIND group was significantly longer than in the other two groups, which indicates stable and high sensitivity of the P300 latency period and the abnormalities during mild cognitive impairment. Correlation analysis shows that the tHcy level in the VCIND group is positively correlated with the P300 latency period, which further supports the association of tHcy levels with impaired cognition.
Conclusions
VCINDpatients have significantly higher levels of tHcy and lower levels of vitamin B12 and folate. The increased tHcy in VCINDpatients may be related to cognitive impairment, which provides a possibility for the treatment of tHcy levels to improve cognitive function in VCINDpatients, which should be confirmed in future research work.This study mainly selected the elderly as the research subjects, and the sample size was relatively small, which might be the limitation of this study. This study also did not consider the effect of folate and vitamin B12 directly on cognitive function. Therefore, we recommended increasing the number of cases and the statistical processing methods in future studies for a more reliable conclusion.
Authors: M Budge; C Johnston; E Hogervorst; C de Jager; E Milwain; S D Iversen; L Barnetson; E King; A D Smith Journal: Ann N Y Acad Sci Date: 2000-04 Impact factor: 5.691
Authors: Tom Skyhoj Olsen; Peter Langhorne; Hans Christoph Diener; Michael Hennerici; Jose Ferro; Johani Sivenius; Nils Gunnar Wahlgren; Philip Bath Journal: Cerebrovasc Dis Date: 2003 Impact factor: 2.762
Authors: Jennifer A McMahon; Timothy J Green; C Murray Skeaff; Robert G Knight; Jim I Mann; Sheila M Williams Journal: N Engl J Med Date: 2006-06-29 Impact factor: 91.245
Authors: Eric R Braverman; Thomas J H Chen; Thomas J Prihoda; William Sonntag; Brian Meshkin; B William Downs; Julie F Mengucci; Seth H Blum; Alison Notaro; Vanessa Arcuri; Michael Varshavskiy; Kenneth Blum Journal: Age (Dordr) Date: 2007-05-12
Authors: Aron M Troen; Melissa Shea-Budgell; Barbara Shukitt-Hale; Donald E Smith; Jacob Selhub; Irwin H Rosenberg Journal: Proc Natl Acad Sci U S A Date: 2008-08-18 Impact factor: 11.205
Authors: Megan C Bakeberg; Alexa Jefferson; Maddeson Riley; Michelle Byrnes; Soumya Ghosh; Frank L Mastaglia; Malcom K Horne; Sarah McGregor; Rick Stell; Jade Kenna; Sue Walters; Dana Hince; Ryan S Anderton Journal: Parkinsons Dis Date: 2019-05-29